CL2023000857A1 - Inhibidores line-1 para tratar la enfermedad - Google Patents

Inhibidores line-1 para tratar la enfermedad

Info

Publication number
CL2023000857A1
CL2023000857A1 CL2023000857A CL2023000857A CL2023000857A1 CL 2023000857 A1 CL2023000857 A1 CL 2023000857A1 CL 2023000857 A CL2023000857 A CL 2023000857A CL 2023000857 A CL2023000857 A CL 2023000857A CL 2023000857 A1 CL2023000857 A1 CL 2023000857A1
Authority
CL
Chile
Prior art keywords
disease
inhibitors
treat
line
individual
Prior art date
Application number
CL2023000857A
Other languages
English (en)
Inventor
Sturino Claudio
Weber Eckard
Doshi Malay
G Cordingley Michael
Original Assignee
Transposon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transposon Therapeutics Inc filed Critical Transposon Therapeutics Inc
Publication of CL2023000857A1 publication Critical patent/CL2023000857A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción provee métodos para tratar o prevenir una enfermedad, trastorno, o condición en un individuo que lo necesita, donde los métodos comprenden administrar al individuo una cantidad terapéuticamente efectiva de un compuesto de la Fórmula I: I, o una sal o solvato farmacéuticamente aceptable de lo mismo, o un tautómero de lo mismo, donde R1, R2, y B se definen como se establece en la descripción.
CL2023000857A 2020-09-23 2023-03-23 Inhibidores line-1 para tratar la enfermedad CL2023000857A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082185P 2020-09-23 2020-09-23
US202163161055P 2021-03-15 2021-03-15

Publications (1)

Publication Number Publication Date
CL2023000857A1 true CL2023000857A1 (es) 2023-11-10

Family

ID=80845827

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000857A CL2023000857A1 (es) 2020-09-23 2023-03-23 Inhibidores line-1 para tratar la enfermedad

Country Status (12)

Country Link
US (1) US20230414616A1 (es)
EP (1) EP4216962A1 (es)
JP (1) JP2023549979A (es)
KR (1) KR20230107543A (es)
AU (1) AU2021347247A1 (es)
CA (1) CA3193512A1 (es)
CL (1) CL2023000857A1 (es)
DO (1) DOP2023000060A (es)
IL (1) IL301564A (es)
MX (1) MX2023003332A (es)
TW (1) TW202228723A (es)
WO (1) WO2022066880A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520132A (ja) * 2021-06-04 2024-05-21 トランスポゾン セラピューティクス インコーポレイテッド 向知性薬としてのｌｉｎｅ－１阻害剤
WO2023178133A1 (en) * 2022-03-15 2023-09-21 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117986A (en) * 1998-06-10 2000-09-12 Intergen Company, L.P. Pyrimidines linked to a quencher
WO2012048113A2 (en) * 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
UA128041C2 (uk) * 2019-01-25 2024-03-20 Браун Юніверсіті Спосіб лікування пов'язаного з віком запалення у пацієнта

Also Published As

Publication number Publication date
CA3193512A1 (en) 2022-03-31
US20230414616A1 (en) 2023-12-28
KR20230107543A (ko) 2023-07-17
IL301564A (en) 2023-05-01
TW202228723A (zh) 2022-08-01
EP4216962A1 (en) 2023-08-02
DOP2023000060A (es) 2023-09-29
JP2023549979A (ja) 2023-11-29
MX2023003332A (es) 2023-06-16
WO2022066880A1 (en) 2022-03-31
AU2021347247A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
CO2023008018A2 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
CL2023001952A1 (es) Inhibidores de alk2 para el tratamiento de la anemia (divisional).
CL2022000781A1 (es) Tratamientos cognitivos medicinales
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
CL2022002317A1 (es) Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.
CO2021018154A2 (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos
BR112022021735A2 (pt) Compostos úteis para inibir cinase ret
BR112022017015A2 (pt) Ureia azalidas imunomoduladoras
UY39593A (es) Tratamiento para tumores sólidos malignos
AR127614A1 (es) Métodos de tratamiento del glioblastoma
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres
AR127115A1 (es) Compuestos heterotricíclicos como inhibidores del gen kras
CO2024003723A2 (es) Compuestos de imidazopiridazina inhibidores de il-17